CatalYm GmbH

6 trials 4 recruiting Commercial sponsor

Filter these 6 trials by condition, phase, country and more.

Open in Search →

6 Registered trials

4 Recruiting

2 Completed trials

11 Countries active

9 Unique IMPs

100% Results reported

Phase II/III

Phase II

Phase I/II

Phase II/III: 1 Phase II: 4 Phase I/II: 1

100%

2 of 2 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Bladder cancer 1

Top IMPs

VISUGROMAB 6 NIVOLUMAB 2 CEMIPLIMAB 1 SODIUM CHLORIDE 1

All trials

6 total

Visugromab in Cachexia International Trial Recruiting

2025-523533-25-00 Phase II/III 11 countries VISUGROMAB
Visugromab, nivolumab and lenvatinib compared to double placebo and lenvatinib in unresectable or metastatic hepatocellular carcinoma post a… Recruiting

2025-520675-86-00 Phase II 4 countries VISUGROMAB
A phase 2 placebo-controlled trial to investigate visugromab in combination with immunochemotherapy (ICT) in first-line treatment of partici… Recruiting

2024-516792-32-01 Phase II 6 countries VISUGROMAB
A phase 2 placebo-controlled trial to investigate visugromab and nivolumab with or without docetaxel in second-line treatment of participant… Recruiting

2024-516794-70-00 Phase II 5 countries VISUGROMAB
A multi-center Phase 2 study of neoadjuvant immunotherapy in combination with the anti-GDF-15 antibody visugromab (CTL-002) for the treatmen… Ended

2024-513957-55-00 Phase II 1 country NIVOLUMAB; SODIUM CHLORIDE; VISUGROMAB
A Phase 1/2, first-in-human, two-part, open-label clinical trial of intravenous administration of CTL-002 given as monotherapy and/or in com… Ended

2024-512575-12-00 Phase I/II 2 countries CEMIPLIMAB; NIVOLUMAB; VISUGROMAB

Showing 1–6 of 6 trials

← All sponsors A–Z